Baker Bros. Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Baker Bros. Advisors’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.3M	Hold	370,208	–	–	0.11%	54
2026 Q1	$21.5M	Hold	370,208	–	–	0.12%	50
2025 Q4	$16.6M	Hold	370,208	–	–	0.1%	59
2025 Q3	$14.9M	Hold	370,208	–	–	0.11%	53
2025 Q2	$11.6M	Buy	370,208 +22,800	+7%	+$744K	0.11%	50
2025 Q1	$11.7M	Sell	347,408 -646,271	-65%	-$24.5M	0.13%	43
2024 Q4	$39M	Hold	993,679	–	–	0.42%	30
2024 Q3	$39.1M	Hold	993,679	–	–	0.41%	29
2024 Q2	$38.7M	Hold	993,679	–	–	0.5%	27
2024 Q1	$42.8M	Hold	993,679	–	–	0.54%	30
2023 Q4	$45.8M	Buy	993,679 +242,040	+32%	+$8.55M	0.52%	24
2023 Q3	$25.7M	Hold	751,639	–	–	0.15%	33
2023 Q2	$28.9M	Hold	751,639	–	–	0.17%	34
2023 Q1	$26.9M	Hold	751,639	–	–	0.15%	32
2022 Q4	$29.6M	Hold	751,639	–	–	0.18%	31
2022 Q3	$27.1M	Hold	751,639	–	–	0.18%	37
2022 Q2	$22.9M	Hold	751,639	–	–	0.13%	44
2022 Q1	$23M	Hold	751,639	–	–	0.13%	50
2021 Q4	$23.5M	Hold	751,639	–	–	0.11%	54
2021 Q3	$11.5M	Hold	751,639	–	–	0.05%	77
2021 Q2	$14M	Hold	751,639	–	–	0.06%	71
2021 Q1	$13.5M	Buy	751,639 +64,253	+9%	+$1.09M	0.06%	69
2020 Q4	$10.6M	Sell	687,386 -72,922	-10%	-$853K	0.04%	73
2020 Q3	$8.42M	Sell	760,308 -38,794	-5%	-$456K	0.03%	70
2020 Q2	$10M	Buy	+799,102	New	+$10.2M	0.04%	60

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Baker Bros. Advisors's XENE Position: Q2 2026 in Review

Baker Bros. Advisors held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 370,208 shares worth $22.3M. The position accounts for 0.11% of the portfolio, ranked #54.

Baker Bros. Advisors first reported a position in XENE in Q2 2020 and has held it in 25 quarters since. The position peaked at $45.8M in Q4 2023. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Baker Bros. Advisors held 370,208 shares of Xenon Pharmaceuticals worth $22.3M as of Q2 2026.
Baker Bros. Advisors left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
Xenon Pharmaceuticals made up 0.11% of Baker Bros. Advisors's portfolio in Q2 2026, its #54 holding.
Baker Bros. Advisors first reported a position in Xenon Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
Baker Bros. Advisors's Xenon Pharmaceuticals position peaked at $45.8M in Q4 2023.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.